Revenue Breakdown
Composition ()
No data
Revenue Streams
Profitability & Margins
Evaluating the bottom line, Catalyst Pharmaceuticals Inc maintains a gross margin of 78.44%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 44.66%, while the net margin is 35.57%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively CPRX converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, CPRX competes directly with industry leaders such as TARS and ERAS. With a market capitalization of $2.96B, it holds a significant position in the sector. When comparing efficiency, CPRX's gross margin of 78.44% stands against TARS's 93.00% and ERAS's N/A. Such benchmarking helps identify whether Catalyst Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.
